Targeting mutant p53 to treat cancer
A novel therapeutic strategy to target mutant p53
This study is exploring a new way to treat cancer by targeting a faulty gene that causes many tumors, especially in triple negative breast cancer, and it hopes to offer patients better treatment options by using a special compound to lower the levels of this gene and slow down cancer growth.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of California at Davis NIH-funded |
| Lab location | 1 site (Davis, United States) |
| Project ID | NIH-11133696 on NIH RePORTER |
What this research studies
This research investigates a new therapeutic approach to target the mutant form of the p53 gene, which is implicated in over half of human cancers. The study focuses on the interaction between specific proteins that enhance the expression of mutant p53, leading to tumor growth and resistance to treatment. By disrupting this interaction with a peptide and a small molecule, the research aims to reduce mutant p53 levels and inhibit cancer cell growth, particularly in triple negative breast cancer. Patients may benefit from new treatment options that specifically address the underlying mechanisms of their cancer.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with triple negative breast cancer or other cancers associated with mutant p53.
Not a fit: Patients with cancers that do not involve mutant p53 may not receive any benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for patients with cancers driven by mutant p53.
How similar studies have performed: Previous research has shown promising results in targeting mutant p53, suggesting that this approach could be a viable therapeutic strategy.
Where this research is happening
Davis, United States
- University of California at Davis — Davis, United States (Active)
Researchers
- Principal investigator: Chen, Xinbin — University of California at Davis
- Study coordinator: Chen, Xinbin
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.